Parvovirus B19 infection in thoracic organ transplant recipients.
BACKGROUND
Clinical manifestations of parvovirus B19 infection in immunocompromised patients are mostly reported as acute or chronic hematologic disorders. More recently, respiratory or renal involvement has been described.


OBJECTIVE
We started in 1994 a prospective study of parvovirus B19 infection in a group of lung (LTP) and heart-lung (HLTP) transplanted patients, including occasionally heart transplanted (HTP) patients.


METHODS
62 patients (49 LTP, 11 HLTP, 2 HTP) were included in a serological survey and DNA detection by PCR was performed on each serum sample of the first 29 patients; later we performed it only when serology could suggest an acute episode, or when parvovirus infection could be suspected on clinical or biological observations. A total of 1655 sera were examined by serological tests and DNA detection was done in 500 samples. Specific IgM, seroconversion, significant increase of specific IgG levels, and/or parvovirus B19 DNA detection, were considered as markers of viral infection.


RESULTS
We observed the presence of both markers of infection in 24 patients (39%), with an individual combination of positive antibody and PCR results. Acute or chronic anaemia, neutropenia were associated to these laboratory findings in 19 patients, but in five cases, an asymptomatic clinical infection suggested viral persistence.


CONCLUSIONS
We report parvovirus associated acute or chronic anaemia and pancytopenia in a group of LTP, HLTP and HTP patients, as well as asymptomatic cases of infection. In the hypothesis of a parvoviral persistent or latent infection, current diagnosis methods may be unreliable to identify any other clinical manifestations.
Calvet
A
A
Laboratoire de Virologie, Domaine Rockefeller, Hôpital Edouard Herriot, Lyon, France. calvet@rockefeller.univ-lyon1.fr
Pujol
M O
MO
Bertocchi
M
M
Bastien
O
O
Boissonnat
P
P
Mornex
J F
JF
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000276:immunology / Q000503:physiopathology / Q000821:virology*; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000276:immunology / Q000503:physiopathology / Q000821:virology*; D010322:Parvoviridae Infections / Q000150:complications / Q000276:immunology / Q000821:virology*; D016732:Parvovirus B19, Human / Q000235:genetics / Q000276:immunology; D011446:Prospective Studies; D012189:Retrospective Studies